Scarica l'app Stockscreener
0.8405
1.23%
-0.0105
Dopo l'orario di chiusura:
.82
-0.0205
-2.44%
Renovorx Inc Borsa (RNXT) Ultime notizie
Guidance Update: Is RenovoRx Inc stock overvalued or fairly pricedJuly 2025 Recap & AI Driven Price Predictions - baoquankhu1.vn
US Market Recap: Whats the outlook for RenovoRx Incs sectorM&A Rumor & AI Enhanced Trading Alerts - baoquankhu1.vn
RenovoRx advances RenovoCath adoption at U.S. cancer centers - Yahoo Finance
RNXT Should I Buy - Intellectia AI
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum - Investing News Network
After 700 cancer procedures, RenovoCath gets new doctor-led commercial push - Stock Titan
Targeted chemo delivery for pancreatic cancer to feature at 2026 SIR meeting - Stock Titan
RNXT PE Ratio & Valuation, Is RNXT Overvalued - Intellectia AI
RenovoRx (RNXT) Price Target Increased by 10.66% to 6.88 - Nasdaq
Hedge Fund Bets: Will eBay Inc Preferred Security stock hit new highs in YEAR2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Is RenovoRx Inc. stock overvalued or fairly pricedSwing Trade & Daily Technical Forecast Reports - mfd.ru
Dow Update: How much upside does RenovoRx Inc haveJuly 2025 Market Mood & Weekly Top Stock Performers List - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) vs. MetaVia (NASDAQ:MTVA) Head-To-Head Survey - Defense World
Mark Voll Joins RenovoRx as Chief Financial Officer - Medical Product Outsourcing
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RenovoRx (NASDAQ:RNXT) Price Target Raised to $13.00 at Ascendiant Capital Markets - Defense World
RenovoRx (RNXT): Analyst Raises Price Target Following Positive Outlook | RNXT Stock News - GuruFocus
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
Why RenovoRx Inc. stock remains resilientTrade Performance Summary & Safe Entry Point Alerts - mfd.ru
Is RenovoRx Inc. a top pick in the sector2025 Biggest Moves & Growth Focused Entry Point Reports - mfd.ru
Can RenovoRx Inc. deliver consistent EPS growthJuly 2025 Trends & Expert Approved Trade Ideas - mfd.ru
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results - MSN
Bank Watch: Can RenovoRx Inc deliver consistent EPS growth2025 Market Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Catalysts: What drives XYZGs stock price2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
What’s the beta of RenovoRx Inc. stockJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
RenovoRx formation of RenovoCath Medical Advisory Board to support clinical and strategic initiatives - marketscreener.com
RenovoRx Forms Medical Advisory Board to Support RenovoCath - Intellectia AI
RenovoRx Establishes RenovoCath® Medical Advisory Board - Investing News Network
Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives - TradingView
RenovoRx, Inc. Establishes Medical Advisory Board to Advance RenovoCath Clinical Initiatives and Targeted Oncology Therapies - Quiver Quantitative
RenovoRx, Inc. Establishes RenovoCath Medical Advisory Board - marketscreener.com
Top radiologists join new board to shape targeted cancer drug delivery - Stock Titan
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Ideas: Is RenovoRx Inc stock overvalued or fairly pricedWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
RenovoRx Appoints Veteran Executive Mark Voll as CFO - TipRanks
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer - Investing News Network
Renovorx, Inc. Appoints Mark Voll as Chief Financial Officer, Effective from February 1, 2026 - marketscreener.com
RenovoRx announces new clinical data on TAMP therapy platform - TipRanks
RenovoRx to Present New Clinical Data on Optimizing Drug Delivery in Solid Tumors at 2026 Society of Interventional Oncology Annual Meeting - Quiver Quantitative
How real-time pressure readings could sharpen chemo targeting - Stock Titan
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting - The Manila Times
Exit Recap: Is SunCar Technology Group Inc Equity Warrant forming a breakout patternJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) Upgraded at Jones Trading - Defense World
Pharma News: How does RenovoRx Inc perform in inflationary periods2025 Volume Leaders & Weekly Momentum Stock Picks - baoquankhu1.vn
Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com - Investing.com South Africa
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Jones Trading initiates coverage on RenovoRx stock with Buy rating - Investing.com
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting - BioSpace
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 S - The National Law Review
RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future - simplywall.st
New catheter study explores tailored chemo delivery for hard-to-treat tumors - Stock Titan
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares By Investing.com - Investing.com Nigeria
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):